Rohto Japan's First OTC Maker To Enter Regenerative Medicines Market
This article was originally published in PharmAsia News
Rohto Pharmaceutical has joined Astellas Pharma and other Japan drug makers in looking into regenerative medicines as the domestic market for that class expects to reach a $2 billion value by 2020.
You may also be interested in...
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.